We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Special Investigation on Long-term Treatment in Patients With Crohn's Disease

This study is ongoing, but not recruiting participants.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01464333
First Posted: November 3, 2011
Last Update Posted: October 18, 2017
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by (Responsible Party):
AbbVie ( AbbVie (prior sponsor, Abbott) )
  Purpose
This study of Humira will be conducted to obtain information on the safety (especially profile of malignant tumors and serious infections) and effectiveness in patients with Crohn's disease who are receiving Humira for a long period of time.

Condition
Crohn's Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Special Investigation (Long-term Investigation) in Patients With Crohn's Disease

Resource links provided by NLM:


Further study details as provided by AbbVie ( AbbVie (prior sponsor, Abbott) ):

Primary Outcome Measures:
  • Number of patients with adverse events [ Time Frame: at month 6 ]
    Occurrence of adverse event (yes or no), nature of adverse events, date of onset, seriousness,clinical course of adverse events, outcome, measures, causal relationship between the event and Humira

  • Number of patients with adverse events [ Time Frame: at year 1 ]
    Occurrence of adverse event (yes or no), nature of adverse events, date of onset, seriousness,clinical course of adverse events, outcome, measures, causal relationship between the event and Humira

  • Number of patients with adverse events [ Time Frame: at year 1.5 ]
    Occurrence of adverse event (yes or no), nature of adverse events, date of onset, seriousness,clinical course of adverse events, outcome, measures, causal relationship between the event and Humira

  • Number of patients with adverse events [ Time Frame: at year 2 ]
    Occurrence of adverse event (yes or no), nature of adverse events, date of onset, seriousness,clinical course of adverse events, outcome, measures, causal relationship between the event and Humira

  • Number of patients with adverse events [ Time Frame: at year 2.5 ]
    Occurrence of adverse event (yes or no), nature of adverse events, date of onset, seriousness,clinical course of adverse events, outcome, measures, causal relationship between the event and Humira

  • Number of patients with adverse events [ Time Frame: at year 3 ]
    Occurrence of adverse event (yes or no), nature of adverse events, date of onset, seriousness,clinical course of adverse events, outcome, measures, causal relationship between the event and Humira


Secondary Outcome Measures:
  • Crohn's Disease Activity Index [ Time Frame: at week 4 ]
  • Crohn's Disease Activity Index [ Time Frame: at month 3 ]
  • Crohn's Disease Activity Index [ Time Frame: at month 6 ]
  • Crohn's Disease Activity Index [ Time Frame: at year 1 ]
  • Crohn's Disease Activity Index [ Time Frame: at year 1.5 ]
  • Crohn's Disease Activity Index [ Time Frame: at year 2 ]
  • Crohn's Disease Activity Index [ Time Frame: at year 2.5 ]
  • Crohn's Disease Activity Index [ Time Frame: at year 3 ]
  • Work Productivity and Activity Impairment Questionnaire [ Time Frame: at week 4 ]
  • Work Productivity and Activity Impairment Questionnaire [ Time Frame: at month 3 ]
  • Work Productivity and Activity Impairment Questionnaire [ Time Frame: at month 6 ]
  • Work Productivity and Activity Impairment Questionnaire [ Time Frame: at year 1 ]
  • Work Productivity and Activity Impairment Questionnaire [ Time Frame: at year 1.5 ]
  • Work Productivity and Activity Impairment Questionnaire [ Time Frame: at year 2 ]
  • Work Productivity and Activity Impairment Questionnaire [ Time Frame: at year 2.5 ]
  • Work Productivity and Activity Impairment Questionnaire [ Time Frame: at year 3 ]

Estimated Enrollment: 500
Study Start Date: December 16, 2011
Estimated Study Completion Date: October 31, 2018
Estimated Primary Completion Date: October 31, 2018 (Final data collection date for primary outcome measure)
Groups/Cohorts
Humira
those with an exposure

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   16 Years to 99 Years   (Child, Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Those who are receiving Humira in accordance with its indications for treatment and dosage regimens.
Criteria

Inclusion Criteria:

  • Patients with Crohn's disease indicated for Humira treatment with the recommended dosage regimen
  • Patients with no past- or present malignant tumors
  • Patients who are not currently receiving Humira

Exclusion Criteria:

  • Contraindications according to the Package Insert
  • Patients who have serious infections
  • Patients who have tuberculosis
  • Patients with a history of hypersensitivity to any ingredient of Humira
  • Patients who have demyelinating disease or with a history of demyelinating disease
  • Patients who have congestive cardiac failure
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01464333


  Show 102 Study Locations
Sponsors and Collaborators
AbbVie (prior sponsor, Abbott)
Investigators
Study Director: Osamu Mikami, MD AbbVie GK
  More Information

Additional Information:
Responsible Party: AbbVie (prior sponsor, Abbott)
ClinicalTrials.gov Identifier: NCT01464333     History of Changes
Other Study ID Numbers: P13-170
First Submitted: November 1, 2011
First Posted: November 3, 2011
Last Update Posted: October 18, 2017
Last Verified: October 2017

Keywords provided by AbbVie ( AbbVie (prior sponsor, Abbott) ):
Crohn's Disease

Additional relevant MeSH terms:
Crohn Disease
Inflammatory Bowel Diseases
Gastroenteritis
Gastrointestinal Diseases
Digestive System Diseases
Intestinal Diseases